Piet Dirix, Michiel Strijbos, Tom Van den Mooter, Nick Liefhooghe, Siska Van Bruwaene, Pieter Uvin, Christophe Ghysel, Dieter Ost, Peter Schatteman, Samuel Bral, et al.
Apalutamide, a competent inhibitor of the androgen receptor, has shown promising clinical efficacy results for patients with advanced prostate cancer. Here, we describe the rationale and design for the SAVE trial, a multi-center, Phase II study, wherein 202 men with biochemical progression after radical prostatectomy are randomly assigned 1:1 to apalutamide plus salvage radiotherapy (SRT) or androgen-deprivation therapy with an luteinizing ...